enGene Inc. (ENGN)
NASDAQ: ENGN
· Real-Time Price · USD
6.50
-0.48 (-6.88%)
At close: Sep 25, 2025, 3:59 PM
6.63
2.00%
After-hours: Sep 25, 2025, 04:17 PM EDT
-6.88% (1D)
| Bid | 6.41 |
| Market Cap | 332.75M |
| Revenue (ttm) | 480K |
| Net Income (ttm) | -43.09M |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -3.42 |
| Forward PE | -2.85 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 6.55 |
| Volume | 43,818 |
| Avg. Volume (20D) | 169,628 |
| Open | 6.97 |
| Previous Close | 6.98 |
| Day's Range | 6.24 - 7.00 |
| 52-Week Range | 2.65 - 11.00 |
| Beta | -0.39 |
| Ex-Dividend Date | n/a |
About ENGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+1.19%
EnGene Holdings shares are trading higher after Pi...
Unlock content with
Pro Subscription
11 months ago
+1.91%
EnGene Holdings shares are trading higher. The company announced it generated approximately $60 million in proceeds from a private placement.
1 month ago · businesswire.com
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducement...
2 months ago · businesswire.com
enGene Announces Board and Leadership Appointments to Support Commercial ReadinessBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of t...
